Search Results - "Burroughs M"

Alloy clustering and its effect on impact ionization in ternary III-V compounds.

Authors: Burroughs, M. S.

Source: Solid-State Electronics; February 1982, Vol. 25, p161-167, 7p

Gabions.

Authors: Burroughs, M. A.

Source: Civil Engineering Asce; January 1979, Vol. 49, p58-61, 4p

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.

Authors: Garcia-Pavia, P. Maron, M. S. Masri, A. et al.

Source: New England Journal of Medicine. 9/11/2025, Vol. 393 Issue 10, p949-960. 12p.

Cytomegalovirus matching does not predict symptomatic disease in intestinal transplantation

Authors: Burroughs, M. Sobanjo, A. Florman, S. et al.

Source: Transplantation Proceedings. May2002, Vol. 34 Issue 3, p946. 2p.

Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin.

Authors: Gordon, S. C. Yoshida, E. M. Lawitz, E. J. et al.

Source: Alimentary Pharmacology & Therapeutics. Jul2013, Vol. 38 Issue 1, p16-27. 12p. 4 Charts, 4 Graphs.

When All Else Fails (Book).

Authors: Burroughs, M. Parker¹

Source: Review of Religious Research; Fall71, Vol. 13 Issue 1, p73, 2p

The Campus Ministry (Book).

Authors: Burroughs, M. Parker¹

Source: Review of Religious Research; Winter68, Vol. 9 Issue 2, p120, 2p

1419 A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN

Authors: Poordad, F.F. Lawitz, E.J. Reddy, K.R. et al.

Source: Journal of Hepatology. Apr2012 Supplement, Vol. 56 Issue s2, pS559-S559. 1p.

484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Authors: Zeuzem, S. Vierling, J.M. Esteban, R. et al.

Source: Journal of Hepatology. Mar2011 Supplement 1, Vol. 54, pS198-S199. 0p.

9 BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS (RAVS) ARE OBSERVED MORE FREQUENTLY IN HCV (GT1)-INFECTED PATIENTS WITH POOR RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN

Authors: Zeuzem, S. Barnard, R.J. Howe, J.A. et al.

Source: Journal of Hepatology. Mar2011 Supplement 1, Vol. 54, pS4-S5. 0p.

481 FOUR-WEEK THERAPY WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN EFFECTIVELY PREDICTS SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE AND PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV-1 TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Authors: Vierling, J.M. Lawitz, E.J. Poordad, F. et al.

Source: Journal of Hepatology. Mar2011 Supplement 1, Vol. 54, pS197-S197. 1p.

452 EFFICACY AMONG NORTH AMERICAN AND EUROPEAN HCV GENOTYPE-1 TREATMENT-NAIVE AND PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Authors: Marcellin, P. Vierling, J.M. Alric, L. et al.

Source: Journal of Hepatology. Mar2011 Supplement 1, Vol. 54, pS184-S184. 1p.

428 ADHERENCE TO ASSIGNED DOSING REGIMEN AND SUSTAINED VIROLOGIC RESPONSE AMONG HEPATITIS C GENOTYPE 1 TREATMENT-NAIVE AND PEG/RIBAVIRIN TREATMENT-FAILURES TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Authors: Gordon, S.C. Lawitz, E.J. Bacon, B.R. et al.

Source: Journal of Hepatology. Mar2011 Supplement 1, Vol. 54, pS173-S174. 0p.

12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY

Authors: Poordad, F. Bronowicki, J.-P. Gordon, S.C. et al.

Source: Journal of Hepatology. Mar2011 Supplement 1, Vol. 54, pS6-S6. 1p.

476 ANEMIA DURING TREATMENT WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN WITH OR WITHOUT BOCEPREVIR IS ASSOCIATED WITH HIGHER SVR RATES: ANALYSIS OF PREVIOUSLY UNTREATED AND PREVIOUS-TREATMENT-FAILURE PATIENTS

Authors: Sulkowski, M.S. Poordad, F. Manns, M.P. et al.

Source: Journal of Hepatology. Mar2011 Supplement 1, Vol. 54, pS194-S195. 0p.

418 UTILITY OF HISTORICAL DATA COMPARED TO LEAD-IN RESPONSE IN PREDICTING SUSTAINED VIROLOGIC RESPONSE IN NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR+PEGINTERFERON ALFA-2B/RIBAVIRIN (P/R)

Authors: Esteban, R. Gordon, S. Lawitz, E. et al.

Source: Journal of Hepatology. Mar2011 Supplement 1, Vol. 54, pS168-S169. 0p.

449 OVERALL SAFETY PROFILE OF BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Authors: Manns, M.P. Felizarta, F. Schiff, E. et al.

Source: Journal of Hepatology. Mar2011 Supplement 1, Vol. 54, pS183-S183. 1p.

448 RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN REDUCES DURATION IN NAIVE AND PEGINTERFERON ALFA-2B/RIBAVIRIN PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV GENOTYPE 1

Authors: Manns, M.P. Poordad, F. Bacon, B.R. et al.

Source: Journal of Hepatology. Mar2011 Supplement 1, Vol. 54, pS182-S183. 0p.

409 PROJECTING THE LONG-TERM CLINICAL IMPACT OF BOCEPREVIR IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE-1 WHO FAILED PRIOR TREATMENT WITH PEGINTERFERON/RIBAVIRIN

Authors: Chhatwal, J. Ferrante, S.A. Dasbach, E.J. et al.

Source: Journal of Hepatology. Mar2011 Supplement 1, Vol. 54, pS164-S164. 1p.

7 BOCEPREVIR IN ADDITION TO STANDARD OF CARE ENHANCED SVR IN HEPATITIS C VIRUS (HCV) GENOTYPE-1 WITH ADVANCED FIBROSIS/CIRRHOSIS: SUBGROUP ANALYSIS OF SPRINT-2 AND RESPOND-2 STUDIES

Authors: Bruno, S. Vierling, J.M. Esteban, R. et al.

Source: Journal of Hepatology. Mar2011 Supplement 1, Vol. 54, pS4-S4. 1p.